Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)
Launched by BAUSCH & LOMB INCORPORATED · Apr 26, 2018
Trial Information
Current as of May 02, 2025
Completed
Keywords
ClinConnect Summary
This is a multicenter, controlled, randomized, monocular trial evaluating the safety and effectiveness of the Bausch \& Lomb DVisc40 dispersive OVD compared to the Alcon VISCOAT® dispersive OVD when used in cataract surgery. Subjects will be randomized to one of the two treatment groups in a 1:1 ratio (DVisc40:VISCOAT®).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The subject must be at least 45 years old and have a clinically documented diagnosis of age-related non-complicated cataract that is considered amenable to treatment with standard phacoemulsification cataract extraction and IOL implantation.
- • 2. The subject must have the capability to provide written informed consent on the Institutional Review Board (IRB)/Ethics Committee (EC) approved Informed Consent Form (ICF) and provide authorization as appropriate for local privacy regulations.
- • 3. The subject must be willing and able to return for all scheduled follow-up examinations through 90 days following surgery.
- • Study #877 Protocol DVisc40 28JUL2017 V1.0 CONFIDENTIAL Page 16 of 53 4. The subject must have clear intraocular media other than the cataract in the operative eye.
- Exclusion Criteria:
- • 1. The subject has participated in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation.
- • 2. The subject has any corneal pathology (e.g., significant scarring, guttata, inflammation, edema, dystrophy, etc.) in the operative eye.
- • 3. The subject has anterior segment pathology likely to increase the risk of an adverse outcome for phacoemulsification cataract surgery (e.g., pseudoexfoliation syndrome, synechiae, iris atrophy, inadequate dilation, shallow anterior chamber, traumatic cataract, lens subluxation) in the operative eye.
- • 4. The subject has any condition which prevents reliable specular microscopy in the operative eye.
About Bausch & Lomb Incorporated
Bausch & Lomb Incorporated is a leading global eye health company dedicated to advancing the vision and well-being of individuals through innovative products and solutions. With a rich history spanning over 160 years, Bausch & Lomb specializes in the development, manufacturing, and marketing of a comprehensive range of eye care products, including contact lenses, lens care solutions, and pharmaceuticals for various ocular conditions. The company is committed to rigorous clinical research and trials to ensure the safety and efficacy of its offerings, striving to enhance patient outcomes and improve quality of life for those with vision-related challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Diego, California, United States
Patients applied
Trial Officials
Anya Loncaric
Study Director
Bausch Health Americas, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials